CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Purpose: Choroideremia (CHM) is a rare inherited retinal degeneration resulting from mutation of the CHM gene, which results in absence of functional Rab escort protein 1 (REP1). We evaluated retinal gene therapy with an adeno-associated virus vector that used to deliver a functional version of the CHM gene (AAV2-REP1). Methods: THOR (NCT02671539) is a Phase 2, open-label, single-center, randomized study. Six male patients (51–60 years) with CHM received AAV2-REP1, by a single 0.1-mL subretinal injection of 10 11 genome particles during vitrectomy. Twelve-month data are reported. Results: In study eyes, 4 patients experienced minor changes in best-corrected visual acuity (−4 to +1 Early Treatment Diabetic Retinopathy Study [ETDRS] letters); one gained 17 letters and another lost 14 letters. Control eyes had changes of −2 to +4 letters. In 5/6 patients, improvements in mean (95% confidence intervals) retinal sensitivity (2.3 [4.0] dB), peak retinal sensitivity (2.8 [3.5] dB), and gaze fixation area (−36.1 [66.9] deg 2 ) were recorded. Changes in anatomical endpoints were similar between study and control eyes. Adverse events were consistent with the surgical procedure. Conclusion: Gene therapy with AAV2-REP1 can maintain, and in some cases, improve, visual acuity in CHM. Longer term follow-up is required to establish whether these benefits are maintained.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No unmanageable inflammation was reported, and modest improvements in visual acuity, contrast sensitivity, and chromatic discrimination thresholds were observed at all doses, consistent with biological activity mediated by vector.92”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [91]
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Self-citationBennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Weleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218
Visual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Self-citationTechnique of retinal gene therapy: delivery of viral vector into the subretinal space
Xue, K., Groppe, M., Salvetti, A. P., & MacLaren, R. E. (2017) · Eye · doi:10.1038/eye.2017.158 · Cited by 191
Self-citationRemodeling of the Human Retina in Choroideremia: Rab Escort Protein 1 (REP-1) Mutations
Jacobson, S. G., Cideciyan, A. V., Sumaroka, A., Aleman, T. S., Schwartz, S. B., Windsor, E. A. M., Roman, A. J., Stone, E. M., & MacDonald, I. M. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0424 · Cited by 174
Aizawa, S., Mitamura, Y., Baba, T., Hagiwara, A., Ogata, K., & Yamamoto, S. (2009) · Eye · doi:10.1038/sj.eye.6703076 · Cited by 163
Test–Retest Variability of Microperimetry Using the Nidek MP1 in Patients with Macular Disease
Chen, F. K., Patel, P. J., Xing, W., Bunce, C., Egan, C., Tufail, A. T., Coffey, P. J., Rubin, G. S., & Da Cruz, L. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2926 · Cited by 146
Choroideremia: A review of general findings and pathogenesis
Coussa, R. G., & Traboulsi, E. I. (2012) · Ophthalmic Genetics · doi:10.3109/13816810.2011.620056 · Cited by 127
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Self-citationGarafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials
Pfau, M., Jolly, J. K., Wu, Z., Denniss, J., Lad, E. M., Guymer, R. H., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100907 · Cited by 165
Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 96
Metadata
- Authors
- Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., Girach, A., Zrenner, E., Ueffing, M., MacLaren, R. E., Bartz-Schmidt, K., & Wilhelm, B.
- Affiliations
- University of Oxford (GB)
- University of Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Nightstar Therapeutics, London, United Kingdom;
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University Eye Hospital, Centre for Ophthalmology, Tübingen, Germany;
- Corresponding author
- Fischer, M. Dominik
- Ochakovski, G. Alex
- Seitz, Immanuel P.
- Vaheb, Yousof
- Kortuem, Constanze
- Reichel, Felix F. L.
- Kuehlewein, Laura
- Zrenner, Eberhart
- MacLaren, Robert E.
- ORCID
- Venue
- Retina
- Published
- 2020-01
- Volume
- 40
- Issue
- 1
- Pages
- 160-168
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2897506831
- Cited by
- 66
- References
- 23
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 10 · 2020: 11
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, adeno-associated virus vectors, Rab escort protein 1, CHM gene, subretinal injection, visual acuity, retinal sensitivity, inherited retinal degeneration
- MeSH terms
- Dependovirus, Genetic Vectors, Humans, Male, Middle Aged, Retina, Visual Acuity, Visual Fields, Vitrectomy, Genetic Therapy, Choroideremia, Parvovirinae, Adaptor Proteins, Signal Transducing, Visual Field Tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. https://app.cochat.ai/papers/10.1097/iae.0000000000002360
- The paper
- Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., Girach, A., Zrenner, E., Ueffing, M., MacLaren, R. E., Bartz-Schmidt, K., & Wilhelm, B. (2020). CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. Retina. https://doi.org/10.1097/iae.0000000000002360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.